The FDA updated safety information for obeticholic acid (Ocaliva) regarding liver injury risk in primary biliary cholangitis (PBC) patients without cirrhosis.
Mayo Clinic Arizona found removing _C. difficile_ from gastrointestinal pathogen panels reduced unnecessary treatments and improved diagnostic stewardship.
Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for hepatitis C met its primary endpoint, demonstrating a 98% SVR12 rate in treatment-adherent patients.
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 treatment did not meet its primary endpoint of reducing all-cause hospitalization or death.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.